Photo: ALM.

The U.S. Food and Drug Administration on Monday approved and authorized for emergency use updated COVID-19 vaccines formulated to target currently circulating variants and provide better protection against serious consequences of COVID-19, including hospitalization and death. The action relates to updated mRNA vaccines for 2023-24 manufactured by Moderna and Pfizer.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Consumer Driven Health Care
Core and Group Health
Compliance
Cost-Containment
Employer-Paid